Hormone Replacement Therapy for Menopause
For a healthy woman under 60 with moderate-to-severe vasomotor symptoms and no contraindications: initiate estrogen-only therapy if she has no uterus, or estrogen plus progestogen therapy if her uterus is intact. 1, 2
Treatment Algorithm Based on Uterine Status
Women WITHOUT a Uterus
- Estrogen monotherapy is the definitive first-line treatment 1, 2
- Both oral and transdermal estrogen have similar efficacy for symptom control 3
- Transdermal estradiol is preferred if moderate cardiovascular risk exists, as it has fewer adverse metabolic effects 1
Women WITH an Intact Uterus
- Estrogen plus progestogen therapy (EPT) is mandatory to prevent endometrial hyperplasia and cancer 1, 2
- For moderate cardiovascular risk: use transdermal estradiol combined with micronized progesterone (or another progestogen that doesn't adversely affect metabolic parameters) 1
- Alternative option: conjugated equine estrogens (CEE) combined with bazedoxifene, which is not associated with increased breast cancer risk (0.25%/year vs 0.23%/year with placebo) 1, 3
Critical Timing Considerations
The "timing hypothesis" is paramount: Women under 60 or within 10 years of menopause onset have the most favorable benefit-risk ratio 1, 4, 5. This age/timing window is when hormone therapy provides cardiovascular protection and bone benefits while minimizing risks of stroke, venous thromboembolism, and dementia that increase with later initiation 4, 6.
Expected Efficacy
Systemic estrogen (with or without progestogen) reduces vasomotor symptom frequency by approximately 75%, making it substantially more effective than nonhormonal alternatives 3. This is the most effective treatment available for bothersome menopausal symptoms 4, 5.
Key Safety Parameters
Absolute Risks in Context
For women in the appropriate age window using CEE with or without medroxyprogesterone acetate, the increased absolute risk is approximately 1 excess event per 1,000 person-years for stroke, venous thromboembolism, and breast cancer (with CEE plus MPA only) 3.
Route Selection Matters
- Transdermal estradiol does not appear to increase venous thromboembolism risk, unlike oral formulations 6
- Oral estrogen carries higher VTE risk compared to transdermal 6
Progestogen Selection
When a progestogen is needed (intact uterus), micronized progesterone is preferred over synthetic progestins as it has a more favorable metabolic and potentially thrombotic profile 1, 7.
Formulation Requirements
Use only FDA-approved preparations and avoid custom-compounded hormones 1. FDA-approved bioidentical estrogens (chemically identical to naturally produced estrogens, often transdermal) are available and appropriate 3.
Shared Decision-Making Elements
Discuss with the patient:
- Choice of formulation (oral vs transdermal)
- Starting dose
- Route of administration
- Individual cardiovascular and breast cancer risk assessment 1
Monitoring and Duration
- Annual reassessment is mandatory to determine if continuation is appropriate 1
- Target the shortest duration consistent with treatment goals, though this doesn't mean arbitrary discontinuation if symptoms persist 1, 4
- For persistent unscheduled bleeding on therapy, evaluate immediately to rule out endometrial pathology 1
- Emphasize adherence to age-appropriate breast cancer screening 1
Common Pitfalls to Avoid
- Don't delay initiation in appropriate candidates—the timing window matters for cardiovascular benefit 4, 6
- Never use estrogen alone in women with an intact uterus—this causes endometrial hyperplasia/cancer 1
- Don't use the outdated "lowest dose for shortest time" mantra rigidly—duration should match documented indications and symptom persistence 7
- Avoid custom-compounded "bioidentical" hormones—these lack FDA oversight and standardization 1